Market Newsdesk

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the Company’s President and CEO, will participate in the following virtual investor conferences during January 2021.

H.C. Wainwright Virtual BioConnect Conference, January 11-14, 2021

To view the on-demand recording of Dr. Mazzo’s presentation at the H.C. Wainwright BioConnect Conference, please visit:

Webcast LINK

.

Biotech Showcase Digital 2021, January 11-15, 2021

To inquire about arranging a virtual meeting with management during the Biotech Showcase, please contact John Menditto, VP of IR and Corporate Communications, at [email protected].

NobleCon17 Investor Conference, January 19-20, 2021

For more information about NobleCon17 and how to participate, please visit

www.nobleconference.com

.

About Caladrius Biosciences

Caladrius Biosciences, Inc. is a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease. We are developing first-in-class cell therapy products based on the finely tuned mechanisms for self-repair that exist in the human body. Our technology leverages and enables these mechanisms in the form of specific cells, using formulations and modes of delivery unique to each medical indication.

The Company’s current product candidates include: HONEDRA® (formerly CLBS12), recipient of SAKIGAKE designation and eligible for early conditional approval in Japan for the treatment of critical limb ischemia (“CLI”) based on the results of an ongoing clinical trial; CLBS14, a Regenerative Medicine Advanced Therapy (“RMAT”) designated therapy for which the Company has finalized with the U.S. Food and Drug Administration (the “FDA”) a protocol for a Phase 3 confirmatory trial in subjects with no-option refractory disabling angina (“NORDA”); CLBS16, the subject of both a recently completed positive Phase 2a study and a newly initiated Phase 2b study in the U.S. for the treatment of coronary microvascular dysfunction (“CMD”); CLBS119, an emergent CD34+ stem cell therapy responding to the COVID-19 pandemic and the potentially permanent damage the virus inflicts on the lungs of many patients; and CLBS201, designed to assess the safety and efficacy of CD34+ cell therapy as a treatment for chronic kidney disease (“CKD”). For more information on the company, please visit www.caladrius.com.

Contact:

Investors:
Caladrius Biosciences, Inc.
John Menditto
Vice President, Investor Relations and Corporate Communications
Phone:  +1-908-842-0084
Email: [email protected]

Media:
W2O Group
Christiana Pascale
Phone: +1-212-257-6722
Email: [email protected]  

• $8 million capital raise supports growth strategies and fulfilling projects yet to be announced
• Financing is expected to advance KULR’s up listing process to a national securities exchange
• Management expects to report strong Q4 2020 revenue

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (OTCQB: KULR) (the “Company” or “KULR”), a leading developer of next-generation thermal management technologies, announces the completion of an $8 million registered direct offering. The Company expects to use the funding to execute its growth initiatives and to fulfill projects yet to be announced. The offering proceeds are expected to help satisfy certain financial criteria for its up listing application to a national securities exchange but no assurances can be made that any application will be approved.

“This financing reflects steady confidence by institutional investors in our technology and long-term direction,” said Michael Mo, CEO of KULR. “We have allocated the net proceeds to expand KULR’s product portfolio, pursue commercial growth opportunities, and repay short-term debt obligations. More importantly, with increased shareholder equity and float, we expect the financing will help advance our up-listing objective, applications for which are currently underway. If approved, up listing could increase awareness of KULR in the investment community, broaden our base of institutional investors, and provide KULR shareholders with increased liquidity.”

Based on an initial review of its performance, KULR anticipates reporting strong Q4 2020 revenues. KULR’s preliminary unaudited estimated revenue for the fourth quarter 2020 is expected to be in the range of $200,000 to $250,000, compared to fourth quarter 2019 revenue of $52,954. Full year 2020 revenue is expected to be in the range of $620,000 to $670,000, compared to $830,938 in full year 2019.

“Our fourth-quarter results are better than expected,” said Simon Westbrook, CFO of KULR. “With this performance some green shoots are emerging that could fuel optimism that the tailwinds of battery safety and electric mobility are starting to converge, with KULR well positioned at the nexus.”

The financial data presented for the fourth quarter of 2020 should be considered preliminary and could be subject to change, as these preliminary results are based on management’s initial analysis of operations and are subject to further internal review and the audit of the Company’s independent auditor. KULR’s actual revenue may differ materially from these preliminary estimates due to, among other things, the completion of KULR’s financial closing procedures.

About KULR Technology Group, Inc.

KULR Technology Group, Inc. (OTCQB: KULR) develops, manufactures and licenses next-generation carbon fiber thermal management technologies for batteries and electronic systems. Leveraging the company’s roots in developing breakthrough cooling solutions for NASA space missions, and backed by a strong intellectual property portfolio, KULR enables leading aerospace, electronics, energy storage, 5G infrastructure and electric vehicle (EV) manufacturers to make their products cooler, lighter and safer for consumers. For more information, please visit www.KULRtechnology.com.

Safe Harbor Statement

This release does not constitute an offer to sell or a solicitation of offers to buy any securities of any entity. This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on May 14, 2020. Forward-looking statements include statements regarding our expectations, beliefs, intentions or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

Media Contact:

Derek Newton
Head, Media Relations
Main: (786) 499-8998
[email protected]

Investor Relations:

KULR Technology Group, Inc.
Main: (888) 367-5559
[email protected]

The Company Records Highest Quarterly Revenue in Seven Years; 

Society6 Group Posts Record Quarterly Revenue and New Customers

SANTA MONICA, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — Leaf Group Ltd. (NYSE: LEAF), a diversified consumer internet company, today provided a financial update. Leaf Group’s fourth quarter 2020 revenue grew over 40% year-over-year – marking its highest quarterly revenue since fiscal year 2013 – reflecting strong growth for Society6 Group and Saatchi Art Group through the end of December 2020, partially offset by lower Media revenue.

“We are proud that Leaf Group delivered another strong quarter in Q4 2020, coming on the heels of our historic revenue growth in Q2 and Q3 of this past year,” said Sean Moriarty, CEO of Leaf Group. “The uncertain macroeconomic environment of 2020 was not without its challenges, but the resilience of our brands and the durability of our portfolio strategy positioned us to deliver outstanding results quarter after quarter this year. Our record new customer growth for both Society6 Group and Saatchi Art Group, the strength of Society6 Group in the $50 billion U.S. online home goods market, and large audience across our digital brands sets us up well for continued success in 2021 and beyond.”

• Society6 Group Gross Transaction Value (GTV)⁽¹⁾ increased over 100% year-over-year in the fourth quarter 2020, driven by overall Direct-to-Consumer (DTC) GTV growth of over 105%, including over 120% growth in the U.S. and over 45% growth internationally. Society6 Group experienced strong demand throughout the holiday period and across its main categories of Wall Art, Home Décor, and Tech Accessories. In addition, Society6 Group acquired record new customers in Q4 2020.
• Saatchi Art Group GTV⁽¹⁾ increased over 20% in Q4 2020, driven by strength in Saatchi Art Online with GTV growth of over 45% and the recently-launched The Other Art Fair Online Studios, partially offset by the postponement or cancellation of its live fairs for the fourth quarter of 2020. In addition, Saatchi Art Online set a record for GTV in Q4 2020.
• Media revenue declined approximately 20% year-over-year in the fourth quarter of 2020 partially due to election-related softness for our lifestyle brands.

“Consumer behavior is continuing to shift online in our main categories of Home, Art & Design and Fitness & Wellness, positioning the company for strong sustained growth. In Q4, we reinvested in new customer acquisition for Society6 resulting in record new customers for the brand, an increase of 14% over our previous record set in Q3 2020,” added Brian Gephart, CFO of Leaf Group. “Our Q4 2020 results have further increased our confidence in surpassing the previously provided 2022 targets of more than $250 million in revenue and $20 million in Adjusted EBITDA, and we expect to provide an update on our outlook in the upcoming Q4 2020 earnings call.”

Leaf Group expects to announce full fourth quarter and full year ended December 31, 2020 financial results in the ordinary course.
______________________
⁽¹⁾ Gross transaction value: Gross transaction value is defined as the total dollar value of Society6 Group and Saatchi Art Group transactions, respectively (excluding, in the case of Saatchi Art Group, the revenue from certain transactions generated by Saatchi Art’s The Other Art Fair, which include sales of stand space to artists at fairs, sponsorship fees and ticket sales). Gross transaction value is the total amount paid by the customer for a Society6 product or Saatchi Art Group artwork, respectively, which consists of the following elements: the product price, inclusive of the commission payable to the artist, shipping charges, and sales taxes, less any promotional discounts. Gross transaction value does not reflect any subsequent cancellations, refunds or credits and does not represent revenue earned by Leaf Group. 

About Leaf Group:

Leaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness and wellness (Well+Good, Livestrong.com and MyPlate App), and home, art and design (Saatchi Art, Society6 and Hunker). For more information about Leaf Group, visit www.leafgroup.com.

Cautionary Information Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. The forward-looking statements set forth in this press release include, among other things, statements regarding the Company’s preliminary financial results, the Company’s future financial performance, the Company’s financial targets for future periods, and the Company’s business and operational strategy.  In addition, statements containing words such as “may,” “believe,” “anticipate,” “expect,” “intend,” “plan,” “project,” “projections,” “business outlook,” “estimate,” “targets,” “guidance,” “guideposts,” or similar expressions constitute forward-looking statements. Actual results may differ materially from the results predicted, and reported results should not be considered an indication of future performance. These forward-looking statements involve risks and uncertainties regarding the Company’s future financial performance; could cause actual results or developments to differ materially from those indicated due to a number of factors affecting Leaf Group’s operations, markets, products and services; and are based on current expectations, estimates and projections about the Company’s industry, financial condition, operating performance and results of operations, including certain assumptions related thereto. Potential risks and uncertainties that could affect the Company’s operating and financial results are described in Leaf Group’s annual report on Form 10-K for the fiscal year ending December 31, 2019 filed with the Securities and Exchange Commission (http://www.sec.gov) on March 16, 2020, as such risks and uncertainties may be updated from time to time in Leaf Group’s quarterly reports on Form 10-Q filed with the Securities and Exchange Commission. These risks and uncertainties include, among others: risks associated with political and economic instability domestically and internationally including those resulting from the COVID-19 pandemic; the Company’s ability to maintain compliance with the continued listing criteria of the New York Stock Exchange; the Company’s ability to obtain forgiveness of its Paycheck Protection Program loan; the Company’s ability to successfully drive and increase traffic to its marketplaces and media properties; the Company’s ability to attract new and repeat customers and artists to its marketplaces and successfully grow its marketplace businesses; the potential impact on advertising-based revenue from lower ad unit rates, a reduction in online advertising spending, a loss of advertisers, lower advertising yields, increased availability of ad blocking software; the Company’s dependence on various agreements with a specific business partner for a significant portion of its advertising revenue; the Company’s history of incurring net operating losses; the Company’s ability to obtain capital when desired on favorable terms; the Company’s ability to effectively integrate, manage, operate and grow acquired businesses; the Company’s ability to generate long-term value for its stockholders; and any future actions that may be taken by activist stockholders. From time to time, the Company may consider acquisitions or divestitures that, if consummated, could be material. Any forward-looking statements regarding financial metrics are based upon the assumption that no such acquisition or divestiture is consummated during the relevant periods. If an acquisition or divestiture were consummated, actual results could differ materially from any forward-looking statements. Any forward-looking statement made by the Company in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to revise or update any forward-looking information, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law, and may not provide this type of information in the future.

Investor Contact:

Shawn Milne
SVP Corporate Finance and Investor Relations
(310) 656-6346
[email protected]

Media Contact:

Sharna Daduk
Vice President, Communications
[email protected]

SUNNYVALE, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — GSI Technology, Inc. (Nasdaq: GSIT), a leading provider of high-performance memory solutions for the networking, telecommunications and military markets, and developer of the Gemini^® Associative Processing Unit (APU) for artificial intelligence, today announced that it has been awarded first prize in the MAFAT Radar Challenge.

GSI Technology was awarded the $25,000 Grand Prize after passing all the competition’s formal and technical eligibility tests. The participants’ challenge consisted of distinguishing between humans and animals in radar signal segments. The challenge provided a rare glimpse of radar signals and its challenges. GSI Technology overcame this challenge through visualization and data manipulation using classic CNN (convolutional neural network) models. For more insights on the challenge, read GSI Technology’s blog post here.

“We are thrilled to be awarded first prize in this very exciting competition, and we would like to thank the MAFAT team for the well-structured material and informative resources they provided to the contestants,” said Lee-Lean Shu, GSI Technology’s Chairman and CEO. “I’d also like to acknowledge the leadership of Daphna Idelson and the GSI team throughout this challenge. This project offered a valuable chance to work with radar signals and their unique challenges—and proved that the GSI team can tackle these challenges with our highly adaptable APU software. This award highlights our chip design capabilities and our strength in software solutions for complex, novel applications. We look forward to participating in the next MAFAT Challenge.”

This year’s MAFAT Radar Challenge focused on the classification of living, non-rigid objects detected by doppler-pulse radar systems. This was the second competition in the MAFAT Challenge series in the field of data science sponsored by the Israeli Ministry of Defense Directorate of Defense Research and Development. The competition was fully open to the academic and industry sectors, as well as to the general public. This effort highlights the value of AI in helping glean intelligence from basic sensor input, which normally is used to detect distance of objects being used to classify the objects themselves.

The competition hosted more than 1,000 registered participants and received more than 4,300 submissions. During the competition, participants received a training data set containing 6,656 radar segments, labeled as either animals or humans, in addition to a supportive (auxiliary) data set containing 49,071 segments. Participants trained their machine learning predictive models based on the training data, and were asked to make predictions for this binary classification task on untagged data (the test set).

ABOUT GSI TECHNOLOGY

Founded in 1995, GSI Technology, Inc. is a leading provider of SRAM semiconductor memory solutions. GSI’s newest products leverage its market-leading SRAM technology. The Company recently launched radiation-hardened memory products for extreme environments and the Gemini^® APU, a memory-centric associative processing unit designed to deliver performance advantages for diverse AI applications. The Gemini APU’s architecture features parallel data processing with two million-bit processors per chip. The massive in-memory processing reduces computation time from minutes to milliseconds, even nanoseconds, while significantly reducing power consumption in a scalable format. Gemini excels at large (billion item) database search applications like facial recognition, drug discovery, Elasticsearch, and object detection. Gemini is ideal for edge applications with a smaller footprint and lower power consumption, where rapid, accurate responses are critical. Headquartered in Sunnyvale, California, GSI Technology has 172 employees, 114 engineers, and over 90 granted patents. For more information on the company and our products, please visit our website at www.gsitechnology.com.

Contacts

Investor Relations

Hayden IR
Kim Rogers
[email protected]
385-831-7337

Media Relations

Finn Partners for GSI Technology
Julie Ortega
[email protected]
510-697-5599

Company

GSI Technology, Inc.
Douglas M. Schirle
Chief Financial Officer
408-331-9802

Sigyn Therapy™ is a Candidate to Treat Life-Threatening Inflammatory Conditions
That Are Not Addressed with Drug Therapies

SAN DIEGO, Jan. 06, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Sigyn Therapeutics, Inc. (OTCMarkets: SIGY), a medical technology company whose focus is the treatment of life-threatening inflammatory conditions precipitated by Cytokine Storm Syndrome (the Cytokine Storm), today announced the results of an in vitro pilot study that successfully modeled the ability of Sigyn Therapy™ to address CytoVesicles that transport inflammatory cytokine cargos in the bloodstream. 

Cytokine Storm Syndrome is an excessive response of the immune system that is induced by infectious and non-infectious conditions. A hallmark indicator of Cytokine Storm Syndrome is the excessive or uncontrolled release of pro-inflammatory cytokines, which can lead to multiple organ failure and cause death.  The annual market opportunity to address Cytokine Storm related indications exceeds $20 billion and includes sepsis, the most common cause of hospital deaths worldwide.  Virus-induced Cytokine Storm Syndrome is a leading cause of death resulting from severe SARS-CoV-2 (COVID-19) infections.

Sigyn Therapy is a proprietary blood purification technology designed to overcome the limitations of previous drug and device candidates to treat acute inflammatory conditions.  Incorporated within Sigyn Therapy is a cocktail of adsorbent components with unique binding and capture characteristics to optimize the broad-spectrum depletion of inflammatory targets from the bloodstream. These targets include pro-inflammatory cytokines, endotoxin and CytoVesicles (extracellular vesicles that transport inflammatory cytokine cargos) that participate in concert with freely circulating cytokines to further escalate the Cytokine Storm.   CytoVesicles are an important yet previously elusive target as they can be 20-60 times larger than cytokines themselves. 

In the in vitro pilot study, 104nm liposomes were utilized as a model system to assess the ability of Sigyn Therapy’s adsorbent components to deplete CytoVesicles from human blood plasma.  After a two-hour interaction with Sigyn’s adsorbent components, liposome concentrations in human blood plasma were reduced ~90%.  Previously published studies have validated liposomes as a model for the isolation of extracellular vesicles from blood based on the similarity of their size and structural characteristics.

“When we designed Sigyn Therapy, we envisioned a device that could be broadly deployed by the medical community, yet also have expansive first-in-industry capabilities that offer to improve patient outcomes,” stated Jim Joyce, Chairman and CEO of Sigyn Therapeutics. “When considering our previous report that Sigyn Therapy™ clears both endotoxin and inflammatory cytokines from human blood plasma, the observation from our CytoVesicle pilot study further reinforces the potential for our vision to become a therapeutic reality.”

Sigyn Therapy is a single-use device designed for use on the established infrastructure of dialysis and CRRT machines already located in hospitals and clinics worldwide. On December 1, 2020, the Company reported the results of an in vitro study that validated the ability of Sigyn Therapy to simultaneously reduce the presence of endotoxin and relevant pro-inflammatory cytokines, which included Interleukin-1 Beta (IL-1B), Interleukin-6 (IL-6) and Tumor Necrosis Factor alpha (TNF-a). Endotoxin (lipopolysaccharide or LPS) is a potent mediator implicated in the pathogenesis of sepsis and septic shock.  The dysregulated over-production of IL-1B, IL-6 and TNF-a can lead to organ failure and cause death.

An objective of the study was to rebalance elevated cytokine levels and optimize the elimination of endotoxin from human blood plasma. The study was conducted in triplicate over four-hour time periods with a pediatric version of Sigyn Therapy.  Average reduction of endotoxin load peaked at 83% during the studies. The average reduction of IL-1B was 69%, IL-6 reduction was 59% and TNF-a reduction was 57% during the four-hour studies.  

The resulting data from each of these studies will be incorporated into an Investigational Device Exemption (IDE) that Sigyn Therapeutics plans to submit to the United States Food and Drug Administration (FDA) in 2021.

About Sigyn Therapeutics

Sigyn Therapeutics™ is a development-stage therapeutic technology company headquartered in San Diego, California USA. Our focus is directed toward a significant unmet need in global health; the treatment of life-threatening inflammatory conditions that are precipitated by Cytokine Storm Syndrome and not addressed with an approved therapy. Our mission is to save lives.

Sigyn Therapy™ is a novel blood purification technology designed to mitigate cytokine storm syndrome through the broad-spectrum depletion of inflammatory targets from the bloodstream. Cytokine storm syndrome is the hallmark of sepsis, which is the most common cause of in-hospital deaths and claims more lives each year than all forms of cancer combined. Virus induced cytokine storm (VICS) is associated with high mortality and is a leading cause of SARS-CoV-2 (COVID-19) deaths. Other therapeutic opportunities include, but are not limited to bacteria induced cytokine storm (BICS), acute respiratory distress syndrome (ARDS) and acute forms of liver failure, such as hepatic encephalopathy.

To learn more, visit www.SigynTherapeutics.com or www.SigynTherapy.com

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements of Sigyn Therapeutics, Inc. (“Sigyn”) that involve substantial risks and uncertainties. All statements contained in this press release are forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “could,” “will,” “plan,” “intend,” “anticipate,” “approximate,” “expect,” “potential,” or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, among others, statements about Sigyn’s future financial performance, the impact of management changes, any proposed organizational restructuring, results of operations, capital resources to fund operations; statements about Sigyn’s expectations regarding the capitalization, resources and ownership structure of the combined company; statements about the potential benefits of the transaction; the expected completion and timing of the transaction and other information relating to the transaction; and any other statements other than statements of historical fact. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that Sigyn makes due to a number of important factors, including (i) the risk that the transaction may not be completed in a timely manner or at all, which may adversely affect Sigyn’s business and the price of the common stock of Sigyn, (ii) the failure to satisfy of the conditions to the consummation of the transaction, (iii) the occurrence of any event, change or other circumstance that could give rise to the termination of the merger agreement, (iv) risks related to the ability to realize the anticipated benefits of the transaction, including the risk that the businesses will not be integrated successfully, (v) the effect of the announcement or pendency of the transaction on Sigyn’s business relationships, operating results and business generally, (vi) risks that the proposed transaction disrupts current plans and operations, (vii) risks related to the combined entity’s ability to up-list to a national securities exchange, (viii) risks related to the combined entity’s access to existing capital and fundraising prospects to fund its ongoing operations, (ix) risks related to diverting management’s attention from Sigyn’s ongoing business operations, (x) other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, and changes in tax and other laws, regulations, rates and policies, and (xi) risks related to an inability to manufacture Sigyn Therapy, risks related to the clinical advancement of Sigyn Therapy with regulatory agencies, and no assurance that Sigyn Therapy will be proven to be a safe and efficacious treatment for any condition. The forward-looking statements in this press release represent Sigyn’s views as of the date of this press release. Sigyn anticipates that subsequent events and developments may cause its views to change. However, while it may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. You should, therefore, not rely on these forward-looking statements as representing Sigyn’s views as of any date subsequent to the date of this press release.

Contact Sigyn Therapeutics, Inc.

Jim Joyce

Chairman, CEO

(619) 368-2000

[email protected]

MINNEAPOLIS, Jan. 06, 2021 (GLOBE NEWSWIRE) — Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, announced today that its wholly owned subsidiary Helomics has completed the integration of Quantitative Medicine’s (QM) novel active-learning Computational Research Engine (CoRE™) with Helomics’ proprietary TumorSpace™ knowledgebase of 150,000 tumor drug response profiles and the TruTumor™ patient primary tumor cell line assay. This integration allows Helomics to offer a revolutionary new AI-driven patient-centric drug discovery service to Pharmaceutical companies that will significantly improve the chances of successfully translating new drugs into the clinic.

“With the completion of the CoRE integration, we are now able to offer our new PeDAL™ (Patient-cEntric Discovery by Active Learning) service to Pharmaceutical companies to allow patient-centric de-risking of compounds early in discovery, resulting in better prioritization of compounds and better coverage of patient diversity. This will dramatically improve the chances of successfully translating discoveries into the clinic, resulting in lowered costs, shortened timelines, and most importantly enhanced “speed-to-patient” for new therapies,” explained Dr. Carl Schwartz, Predictive Oncology, CEO. “We expect to see revenue generating projects that use PeDAL and CoRE in the first half of 2021,” commented Dr. Schwartz.

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Skyline, Helomics and Soluble Biotech), which contain four subsidiaries: Helomics, TumorGenesis, Skyline Medical and Soluble Biotech.

Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. TumorGenesis Inc. specializes in media that help cancer cells grow and retain their DNA/RNA and proteomic signatures, providing researchers with a tool to expand and study cancer cell types found in tumors of the blood and organ systems of all mammals, including humans. Skyline Medical markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement, and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. Soluble Biotech is a provider of soluble and stable formulations for proteins including vaccines, antibodies, large and small proteins, and protein complexes.

Forward-Looking Statements

Certain matters discussed in this release contain forward-looking statements. These forward-looking statements reflect our current expectations and projections about future events and are subject to substantial risks, uncertainties and assumptions about our operations and the investments we make. All statements, other than statements of historical facts, included in this press release regarding our strategy, future operations, future financial position, future revenue and financial performance, projected costs, prospects, plans and objectives of management are forward-looking statements. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “would,” “target” and similar expressions are intended to identify forward- looking statements, although not all forward-looking statements contain these identifying words. Our actual future performance may materially differ from that contemplated by the forward-looking statements as a result of a variety of factors including, among other things, factors discussed under the heading “Risk Factors” in our filings with the SEC. Except as expressly required by law, the Company disclaims any intent or obligation to update these forward-looking statements.

Investor Relations Contact:

Landon Capital
Keith Pinder
(404) 995-6671
[email protected]

 

AUSTIN, Texas, Jan. 06, 2021 (GLOBE NEWSWIRE) — Asure (NASDAQ:ASUR), a leading provider of cloud-based Human Capital Management (HCM) software solutions, announces a new leadership structure, including three appointments to the executive team to further its corporate vision and drive growth.

“John Pence, Todd Waletzki and Yasmine Rodriguez each come to Asure with impressive track records and HCM expertise.   Their industry experience adds tremendous depth to our leadership team and will help us drive our growth strategy. Their new leadership brings a renewed commitment to Asure’s HCM vision,” stated Pat Goepel, CEO of Asure. “Each of them are uniquely suited to maximize Asure’s strengths and position the company for continued growth in the years ahead. Today marks a new way forward for our company.”

John Pence recently joined Asure as the Company’s Chief Financial Officer. Pence has nearly 30 years of leadership experience in accounting, finance, and operations at a variety of both publicly-traded and privately-held technology companies that served both large and small businesses. In this new role, John is responsible for formulating and executing financial and operational strategies to achieve the company’s strategic goals. Most recently, he served as CFO of a HR benefits provider and helped direct a successful exit for the company’s investors.

Todd Waletzki has joined Asure as Chief of Staff. Waletzki brings more than 30 years of relevant industry and operations experience with a focus on leading technology enabled service businesses. At Asure, he will be responsible for driving key strategic and internal process improvement initiatives across the company. Prior to Asure, he served as President of the Payroll division at BenefitMall, Inc and Chief Operating Officer for CompuPay, Inc. Waletzki also held senior level operating positions at Capital One, AOL and Sprint.

Yasmine Rodriguez join as Sr. Vice President and General Manager, Tax & Compliance. Rodriguez has over 20 year of tax and compliance expertise and lead a development team in the creation of a Payroll Tax application TaxEx. At Asure, she will continue to enhance and ensure compliance with constantly changing regulations. Recently, she served as VP of Product Management and RPA at OneSource Virtual. Rodriguez also held positions as VP & Co-Founder of Crystal Solution – TaxEx, ADP and MasterTax.

“I am pleased with the incoming talent and their expertise as well as the positioning of the board and management team, I am confident we are going to capitalize on our momentum and have a successful future,” Goepel stated.

About Asure Software

Asure (NASDAQ: ASUR) sees Human Capital Management (HCM) through the lens of entrepreneurs and executives with an owner’s mentality. We help more than 60,000 small and mid-sized businesses develop their “Human Capital” to get to the next level, stay compliant, and allocate their time, money and technology toward growth. Asure HCM solution includes Asure Payroll & Tax, Asure HR, and Asure Time & Attendance. Our Asure HRServices offer ranges from online compliance tools to a fully outsourced HR department. Visit us at asuresoftware.com.

Company Contact:

Stacy Zellner, Director of Marketing
(512) 843-7567
[email protected]

Investor Contact:

Jeff Houston, Director Corporate Development
(512) 437-2349
[email protected]

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at two upcoming investor conferences and participate in a panel discussion hosted by former FDA Commissioner, Scott Gottlieb, M.D.:

• 39th Annual J.P. Morgan Healthcare Conference
  
  Wednesday, January 13 at 11:40 a.m. Eastern Time

• H.C. Wainwright Virtual BioConnect Conference
  
  On-demand presentation available beginning Monday, January 11 at 6:00 a.m. Eastern Time

• Clinical
  Trial
  Panel
  Discussion
  at the H.C. Wainwright Virtual BioConnect Conference
  Monday, January 11 at 12:00 p.m. Eastern Time

Live audio webcasts of the J.P. Morgan presentation and H.C. Wainwright Clinical Trials Panel and on-demand presentation can be accessed through the Investors section of the Company’s website at www.ChemoCentryx.com. Replays of both the J.P. Morgan and H.C. Wainwright presentations will be available on the Company’s website for two weeks following the respective presentation dates.

About ChemoCentryx

ChemoCentryx is a biopharmaceutical company developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally administered therapies. ChemoCentryx’s lead drug candidate, avacopan (CCX168), successfully completed a pivotal Phase III trial in ANCA-associated vasculitis and a New Drug Application is under review by the U.S. Food and Drug Administration, along with a Marketing Authorization Application by the European Medicines Agency. Avacopan is also in late-stage clinical development for the treatment of Hidradenitis Suppurativa and C3 glomerulopathy (C3G).

ChemoCentryx also has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer.

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
[email protected]

Media:
Stephanie Tomei
408.234.1279
[email protected]

Investors:
Lee Roth, Burns McClellan
212.213.0006
[email protected]

VANCOUVER, British Columbia, Jan. 06, 2021 (GLOBE NEWSWIRE) — Standard Uranium Ltd. (“Standard Uranium” or the “Company”) (TSX-V:STND) (OTCQB:STTDF) (Frankfurt:FWB:9SU) is pleased to announce that it has received approval from the OTC Market Group Inc. to commence trading on the OTCQB Venture Market under the ticker symbol “STTDF” at the opening of the trading day on January 6, 2021. Standard Uranium’s shares will continue to trade on the TSX Venture Exchange.

The OTCQB offers transparent trading in entrepreneurial and development stage companies that have met a minimum bid price test, are current in their financial reporting and have undergone an annual verification and management certification process. These standards provide a strong baseline of transparency, as well as the technology and regulation to improve the information and trading experience for investors.

“Standard Uranium is excited to be listing on the OTCQB Venture Market. We believe a secondary listing on this market will provide the Company with increased access to US institutional and retail investors and a broader shareholder base. U.S. investors will have the opportunity to share in the Company’s growth as investor interest in clean energy and the benefits of nuclear power and the uranium industry gain momentum,” said Jon Bey, President and CEO. “U.S. investors can find Real-Time quotes and market information for Standard Uranium at www.otcmarkets.com and access current company news and developments.”

Standard Uranium is also pleased to announce that it has granted a total of 750,000 stock options to certain executives, directors and consultants of the Company. The stock options have been granted pursuant to the Company’s stock option plan and will vest as follows: 25% vesting three months from the date of grant, 25% vesting six months from the date of grant, 25% vesting nine months from the date of grant and 25% vesting 12 months from the date of grant. The stock options have an exercise price of $0.20 per share and will expire five years from the date of grant.

About Standard Uranium

We find the fuel to power a


clean energy


future

Standard Uranium is a mineral resource exploration company based in Vancouver, British Columbia. Since its establishment, Standard Uranium has focused on the identification and development of prospective exploration stage uranium projects in the Athabasca Basin in Saskatchewan, Canada. Standard Uranium’s Davidson River Project, in the southwest part of the Athabasca Basin, Saskatchewan, is comprised of 21 mineral claims over 25,886 hectares. The Davidson River Project is highly prospective for high-grade, basement hosted uranium deposits. A copy of the NI 43-101 Technical Report that summarizes the exploration on the Project is available for review under Standard Uranium’s SEDAR issuer profile (www.sedar.com).

For further information contact:

Jon Bey, President, Chief Executive Officer, and Chairman
550 Denman Street, Suite 200
Vancouver, BC V6G 3H1
E-mail: [email protected]

Cautionary Statement Regarding Forward-Looking Statements

This news release contains “forward-looking statements” or “forward-looking information” (collectively, “forward-looking statements”) within the meaning of applicable securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on the assumptions, expectations, estimates and projections as of the date of this news release.   Forward-looking statements are subject to a variety of known and unknown risks, uncertainties and other factors that could cause actual events or results to differ from those expressed or implied by forward-looking statements contained herein. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Standard Uranium disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by applicable securities laws. Readers should not place undue reliance on forward-looking statements.

Neither TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accepts responsibility for the adequacy or accuracy of this release.

NEW YORK, Jan. 06, 2021 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in three virtual investor conferences in January 2021.

Details of the events are as follows:

• 10^th Annual LifeSci Partners Corporate Access Event: The company will host virtual one-on-one meetings during the conference on Wednesday, January 6 through Friday, January 8 and Monday, January 11 through Thursday, January 14, 2021.
• H.C. Wainwright Virtual BioConnect Conference: The company’s presentation will be available for on-demand viewing on Checkpoint’s website beginning Monday, January 11, 2021, at 6:00 a.m. EST.
• B. Riley Securities’ Virtual Oncology Investor Conference: The company’s presentation will take place on Thursday, January 21, 2021, at 10 a.m. EST and will be available to all conference-registered institutional investors.

Webcasts of the H.C. Wainwright and B. Riley presentations will be available on the Events page, located within the Investors section of Checkpoint’s website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days following each presentation.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. (“Checkpoint”) is a clinical-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization of novel treatments for patients with solid tumor cancers. Checkpoint is evaluating its lead antibody product candidate, cosibelimab, a potential best-in-class anti-PD-L1 antibody licensed from the Dana-Farber Cancer Institute, in an ongoing global, open-label, multicohort Phase 1 clinical trial in checkpoint therapy-naïve patients with selected recurrent or metastatic cancers, including ongoing cohorts in locally advanced and metastatic cutaneous squamous cell carcinoma intended to support one or more applications for marketing approval. In addition, Checkpoint is evaluating its lead small-molecule, targeted anti-cancer agent, CK-101, a third-generation epidermal growth factor receptor (“EGFR”) inhibitor, as a potential new treatment for patients with EGFR mutation-positive non-small cell lung cancer. Checkpoint is headquartered in New York City and was founded by Fortress Biotech, Inc. (NASDAQ: FBIO). For more information, visit www.checkpointtx.com.

Forward‐Looking Statements

This press release may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Such statements include, but are not limited to, any statements relating to our plans to submit one or more Biologics License Applications and seek approvals for cosibelimab, statements regarding the potential differentiation of cosibelimab, including a potentially favorable safety profile as compared to the currently available anti-PD-1 therapies, statements relating to the half-life and functional Fc domain of cosibelimab translating into potential enhanced efficacy, statements relating to the timing of the completion of enrollment and full top-line results, statements relating to how long we believe our cash will fund our operations, any statements relating to our growth strategy, product development programs and commercial prospects, and any other statements that are not historical facts. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include: risks that regulatory authorities will not accept an application for approval of cosibelimab based on data from the ongoing Phase 1 study; risks relating to our growth strategy and commercial prospects; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; risks relating to the results of research and development activities; risks relating to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our Securities and Exchange Commission filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.

Company Contacts:

Jaclyn Jaffe and William Begien
Checkpoint Therapeutics, Inc.
(781) 652-4500
[email protected]

Investor Relations Contact:

Ashley R. Robinson
Managing Director, LifeSci Advisors, LLC
(617) 430-7577
[email protected]

Media Relations Contact:

Eddie Kraft
Affect
(212) 398-9680
[email protected]